Additional Study Information: The purpose of this study is to test the effectiveness of investigational drug APL-130277 for patients with Parkinson's disease. APL-130277 is an investigational drug, which means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). The active ingredient in APL-130277 is apomorphine, a medication that has been used in an injectable form for many years to treat OFF episodes in patients with Parkinsons disease (PD). APL-130277 is a fast acting thin film formulation of apomorphine that is placed under the tongue, similar to a breath strip used to freshen your breath. APL-130277 is intended to be an alternative to the injectable form of apomorphine, whichis known under the brand name APOKYN, and is given as an injection under the skin.